Alligator Bioscience Adds Seasoned Pharma Leaders to Proposed Board Slate

An update from Alligator Bioscience AB ( (SE:ATORX) ) is now available.

Alligator Bioscience’s nomination committee has proposed the re-election of Hans-Peter Ostler and Denise Goode as ordinary board members and the election of industry veterans Anna Törner and Jörg Möller as new ordinary board members, with Ostler also nominated to continue as chairman. Existing board member Eva Sjökvist Saers has declined re-election.

Törner brings deep regulatory, statistical and late-stage drug development expertise from her work in pharma, academia and as founder and former CEO of SDS Life Science, while Möller adds over three decades of global R&D leadership from major pharmaceutical and biotech companies including Bayer and Leo Pharma. Both proposed directors are deemed independent of the company, its management and major shareholders, signaling a continued emphasis on strong governance and seasoned external oversight ahead of the annual shareholders’ meeting on 6 May 2026.

The most recent analyst rating on (SE:ATORX) stock is a Sell with a SEK0.16 price target. To see the full list of analyst forecasts on Alligator Bioscience AB stock, see the SE:ATORX Stock Forecast page.

More about Alligator Bioscience AB

Alligator Bioscience AB is a Swedish biotechnology company based in Lund, focused on developing antibody-based immuno-oncology therapies. The company operates within the pharmaceutical and biotech R&D space, targeting advanced cancer treatments and collaborating with industry experts and investors to progress its clinical and preclinical pipeline.

YTD Price Performance: -48.81%

Average Trading Volume: 5,244,947

Technical Sentiment Signal: Strong Sell

Current Market Cap: SEK91.94M

Find detailed analytics on ATORX stock on TipRanks’ Stock Analysis page.